NAIXIONG PENG, YUEFENG CAI, DONG CHEN, LING DENG, ZEJIAN ZHANG, WEI LI^*

Oncology Research, Vol.33, No.2, pp. 347-356, 2025, DOI:10.32604/or.2024.056039 - 16 January 2025

Abstract Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to… More >

JESSIE REYES-CARMONA^*

Oncology Research, Vol.33, No.2, pp. 301-307, 2025, DOI:10.32604/or.2024.053764 - 16 January 2025

Abstract The B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) protein of the polycomb complex is an essential mediator of the epigenetic transcriptional silencing by the chromatin structure. It has been reported to be crucial for homeostasis of the stem cells and tumorigenesis. Though years of investigation have clarified Bmi-1’s transcriptional regulation, post-translational modifications, and functions in controlling cellular bioenergetics, pathologies, and DNA damage response, the full potential of this protein with so many diverse roles are still unfulfilled. Bmi-1 is overexpressed in many human malignancies. Unraveling the Bmi-1’s precise functional role in head and neck… More >

GAMALELDIN I. HARISA^1,*, RIYAD F. ALZHRANI¹, ABDULRAHMAN A. ALLUHAIDAN¹, SULTAN M. ALAMRI¹, AHMED H. BAKHEIT², HANADI H. ASIRI², SABRY M. ATTIA³

Oncology Research, Vol.33, No.2, pp. 477-492, 2025, DOI:10.32604/or.2024.053337 - 16 January 2025

Abstract Background: Hepatocellular carcinoma (HCC) is a health problem due to multi-drug resistance (MDR). Codelivery of multiple oncotherapy in one cargo as chimeric cancer therapy (CCT) is suggested as a solution for MDR. This study aims to engineer chitosan-coated nanostructure lipid carriers (NLCs) loaded with gefitinib (GF) and simvastatin (SV) as CCT for HCC. Methods: Both GF and SV-loaded nanostructure lipids carriers (GFSVNLC) and chitosan-capped GF and SV-loaded nanostructure lipids carriers (CGFSVNLC) formulations were assembled by top-down techniques. Moreover, particle size (PS), zeta potential (ZP), and polydispersity index (PDI) were measured by Zetasizer. The biosafety of… More > Graphic Abstract

LIANGJIANG XIA¹, GUANGBIN LI², QINGWU ZHOU³, YU FENG^2,*, HAITAO MA^2,*

Oncology Research, Vol.33, No.2, pp. 465-475, 2025, DOI:10.32604/or.2024.050835 - 16 January 2025

Abstract Background: Circular RNAs play an important role in regulating lung adenocarcinoma (LUAD). Bioinformatics analysis identified circ_0015278 as differentially expressed in LUAD. However, the biological mechanism of circ_0015278 in LUAD has not been fully clarified, especially in ferroptosis. Materials and Methods: Bioinformatics analysis was employed to explore the downstream mechanisms of Circ_0015278, subsequently confirmed by luciferase reporter assays. The impact of Circ_0015278 on cell proliferation, migration, invasion, and ferroptosis was investigated through a loss-of-function experiment. A xenotransplantation mouse model elucidated the effect of Circ_0015278 on tumour growth. Results: Circ_0015278 exhibited downregulation in LUAD. It inhibited cell proliferation, More >

QI LV^1,#, GANGMIN WANG^2,#, YI HONG¹, TIANYI ZHU¹, SHUANG QIN¹, SAIFEI SUN¹, YUTING WANG¹, YAOHUA LIU¹, QING ZHANG¹, CHUNHUI MA^3,*, PEIJUN WANG^1,*

Oncology Research, Vol.33, No.2, pp. 407-420, 2025, DOI:10.32604/or.2024.047698 - 16 January 2025

Abstract Background: Sunitinib resistance is a major challenge in advanced renal cell carcinoma (RCC). Clinically, elucidating the underlying mechanisms and developing practical countermeasures for sunitinib resistance in RCC is desirable. In previous studies, we found that circAGAP1 expression was significantly upregulated in clear cell RCC (ccRCC) and was strongly associated with poor prognosis. However, the role of circAGAP1 in sunitinib resistance in ccRCC remains unclear. Methods: We used public databases for bioinformatics analysis to identify the binding targets of circAGAP1. Additionally, the effects of circAGAP1 on the proliferation, clonogenesis, apoptosis, and migration of ccRCC cells were… More > Graphic Abstract

SHUO YU, MIN WANG, XU LI, XINGJUN GUO, RENYI QIN^*

Oncology Research, Vol.33, No.2, pp. 369-380, 2025, DOI:10.32604/or.2024.046774 - 16 January 2025

Abstract Background: Circular RNAs (circRNAs) play a pivotal role in the development and advancement of various cancer types. However, the involvement of circ-PAN3 in hepatocellular carcinoma (HCC) is not well understood. To shed light on this, we conducted a comprehensive study through biochemistry, cell biology, molecular biology, and bioinformatics techniques to investigate the role of circ-PAN3 and its associated pathway in the progression of HCC. Methods: Cell Counting Kit-8 (CCK-8) assay and colony formation assay were utilized to evaluate cell proliferation; Quantitative real-time PCR (RT-qPCR) and Western blot were adopted for assessing mRNA and protein expression;… More >

HAIYING PANG^1,#, FENGBO WU^1,#, YU ZHANG¹, NAN ZHANG², CHUNTING WANG¹, QIU LI¹, GU HE^1,*, PENG ZHANG^3,*

Oncology Research, Vol.33, No.2, pp. 443-464, 2025, DOI:10.32604/or.2024.043948 - 16 January 2025

Abstract Background: EMP2 is a tumor-associated membrane protein belonging to the GAS-3/PMP22 gene family. EMP2 expression demonstrates significant tissue specificity and heterogeneity in various human tissues and tumor tissues, where it may play a role in either promoting or inhibiting tumor growth. This study aimed to investigate the expression level, biological functions, and molecular mechanisms of EMP2 in liver cancer. Methods: we analyzed the mRNA expression levels of EMPs family genes in hepatocellular carcinoma (HCC) tissues and normal liver tissues based on the TCGA database and immunohistochemical analysis of tissue microarrays. Subsequently, we constructed HCC cell… More > Graphic Abstract

YUEZHOU ZHANG^1,#, ZHAO ZHANG^2,#, JINXIN DONG¹, CHANGAN LIU^1,*

Oncology Research, Vol.33, No.1, pp. 83-102, 2025, DOI:10.32604/or.2024.055866 - 20 December 2024

Abstract Background: Aberrant expression of RNA-binding proteins (RBPs) has been linked to a variety of diseases, including hematological disorders, cardiovascular diseases, and multiple types of cancer. Heterogeneous nuclear ribonucleoprotein C (HNRNPC), a member belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family, plays a pivotal role in nucleic acid metabolism. Previous studies have underscored the significance of HNRNPC in tumorigenesis; however, its specific role in malignant tumor progression remains inadequately characterized. Methods: We leveraged publicly available databases, including The Cancer Genome Atlas (TCGA), to explore the potential involvement of HNRNPC across various cancers. Additionally, we performed experimental… More > Graphic Abstract

NASSER MULLA^1,*, YOUSEF KATIB², ASIM M. ALMUGHAMSI³, DUAA S. ALKHAYAT¹, MOHAMED MOSAAD^1,4, SAMIR T. ALFOTIH⁵, RAWAN ALAOFI⁶

Oncology Research, Vol.33, No.1, pp. 149-160, 2025, DOI:10.32604/or.2024.050903 - 20 December 2024

Abstract Background: Hepatocellular carcinoma (HCC) is the most common cause of cancer-related death in Saudi Arabia. Our study aimed to investigate the patterns of HCC and the effect of TNM staging, Alfa-fetoprotein (AFP), and Child-Turcotte Pugh (CTP) on patients’ overall survival (OS). Methods: A retrospective analysis was conducted on 43 HCC patients at a single oncology center in Saudi Arabia from 2015 to 2020. All patients had to fulfill one of the following criteria: (a) a liver lesion reported as definitive HCC on dynamic imaging and/or (b) a biopsy-confirmed diagnosis. Results: The mean patient age of all… More >

LEI WANG¹, XIANJIN XIE^2,*

Oncology Research, Vol.33, No.1, pp. 123-132, 2025, DOI:10.32604/or.2024.048562 - 20 December 2024

Abstract Background: To investigate SCL/TAL 1 interrupting locus (STIL)’s role and prognostic significance in lung adenocarcinoma (LUAD) progression, we examined STIL and E2 promoter binding factor 1 (E2F1) expression and their impacts on LUAD prognosis using Gene Expression Profiling Interactive Analysis (GEPIA). Methods: Functional assays including CCK-8, wound-healing, 5-ethynyl-2-deoxyuridine (EdU), Transwell assays, and flow cytometry, elucidated STIL and E2F1’s effects on cell viability, proliferation, apoptosis, and migration. Gene set enrichment analysis (GSEA) identified potential pathways, while metabolic assays assessed glucose metabolism. Results: Our findings reveal that STIL and E2F1 are overexpressed in LUAD, correlating with adverse outcomes. It enhances More >